Overview

A Study to Evaluate the Effect of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease

Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to assess the magnitude of the baseline difference between participants with early Huntington's Disease (HD) and healthy participants (HP) with respect to measures of cognitive performance and the effect of SAGE-718 on cognitive performance and functioning in participants with HD.
Phase:
Phase 2
Details
Lead Sponsor:
Sage Therapeutics